Azzad Asset Management Inc. ADV Grows Position in AstraZeneca PLC (NASDAQ:AZN)

Azzad Asset Management Inc. ADV increased its position in AstraZeneca PLC (NASDAQ:AZN) by 1.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 63,127 shares of the company’s stock after purchasing an additional 895 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in AstraZeneca were worth $4,640,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in AZN. Brighton Jones LLC lifted its stake in shares of AstraZeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of AstraZeneca by 0.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 85,127 shares of the company’s stock valued at $5,578,000 after purchasing an additional 616 shares during the period. Focus Financial Network Inc. lifted its stake in shares of AstraZeneca by 20.3% in the 4th quarter. Focus Financial Network Inc. now owns 6,369 shares of the company’s stock valued at $417,000 after purchasing an additional 1,074 shares during the period. Allspring Global Investments Holdings LLC increased its position in AstraZeneca by 153.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 153,695 shares of the company’s stock valued at $10,125,000 after buying an additional 93,071 shares in the last quarter. Finally, Van ECK Associates Corp increased its position in AstraZeneca by 3.3% during the 4th quarter. Van ECK Associates Corp now owns 459,560 shares of the company’s stock valued at $30,110,000 after buying an additional 14,768 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price objective for the company. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $85.00.

AstraZeneca Stock Performance

NASDAQ AZN opened at $74.42 on Friday. The firm has a market cap of $230.80 billion, a price-to-earnings ratio of 32.93, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $69.81 and a 200-day moving average price of $70.26. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same period in the prior year, the company earned $2.06 earnings per share. The firm’s revenue was up 7.2% on a year-over-year basis. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.